Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:8:79-86.
doi: 10.2147/TCRM.S23875. Epub 2012 Feb 17.

Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus

Mao Hagihara  1 , Takumi Umemura, Takeshi Mori, Hiroshige Mikamo
Affiliations

Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus

Mao Hagihara et al. Ther Clin Risk Manag. 2012.

Abstract

Daptomycin is a lipoglycopeptide antibacterial drug that is rapidly bactericidal for methicillin-resistant Staphylococcus aureus (MRSA) infection and has antibiotic activity against a wide range of Gram-positive organisms. It has been approved by the Ministry of Health, Labor and Welfare in Japan for the treatment for bacteremia, right-sided endocarditis, and skin and skin-structure infections, such as necrotizing fasciitis, due to MRSA on the basis of a Phase III trial conducted in Japan since July, 2011. In Japanese Phase I and III trials, daptomycin therapy given at 4 mg/kg and 6 mg/kg once per day was well tolerated and effective as standard therapy for the treatment of acute bacterial skin and skin-structure infections and bacteremia caused by MRSA, but side effects remain to be evaluated in large-scale trials.

Keywords: Japan; daptomycin; methicillin-resistant Staphylococcus aureus (MRSA).

PubMed Disclaimer

References

    1. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg Infect Dis. 2007;13:1840–1846. - PMC - PubMed
    1. Japan Nosocomial Infections Surveillance [homepage on the Internet] Japan Nosocomial Infections Surveillance Report. [Accessed February 7, 2012]. Available from: http://www.nih-janis.jp/report/open_report/2010/2/1/ken_Open_Report_2010.... Japanese.
    1. National Nosocomial Infections Surveillance. National Nosocomial Infections Surveillance system report, data summary from January 1992 through June 2004. Am Infect Control. 2004;32:470–485. - PubMed
    1. Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004;38:521–528. - PubMed
    1. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448–451. - PubMed